Leech Therapy

Early records and traditional medical systems

A 2026 scoping review of leech-derived compounds reports that the earliest recorded use of leeches dates to about 1500 BCE, citing an Egyptian tomb painting, and that Hippocrates and Galen used leech bloodletting within Greco-Roman humoral theory, in which disease was attributed to an imbalance of blood, phlegm and bile. The review is a secondary summary, and the primary evidence for these dates was not checked here.

The same review states that leech therapy continued in Ayurvedic, Unani and Persian medicine after it declined in Europe. It describes an Ayurvedic text with a section on leech application (jalaukacharana), and says Avicenna and Abdul Latif Baghdadi recorded leeches for up to 125 ailments. These practices belong to distinct traditions and should not be read as one continuous lineage.

Decline and modern surgical revival

The scoping review says leech therapy faced growing skepticism as humoral theory fell out of favor, and that a biomedical revival began in the late 1980s in microsurgery and reconstructive surgery, where leeches are applied to relieve venous congestion. It links this revival to biochemical studies of leech saliva, which contains anticoagulant, platelet-inhibiting and other active molecules.

A hospital pharmacy study from France describes hirudotherapy as an empirical medical technique that has become popular again in reconstructive surgery. Modern surgical use differs from historical bloodletting in its stated purpose, which is local drainage of a congested tissue rather than correcting a systemic imbalance.

Device status in the United States

The US Food and Drug Administration (FDA) device database lists a 510(k) premarket notification, K040187, for a product named Medicinal Leeches from a French applicant, with a decision date of June 21, 2004 and a finding of substantial equivalence. The product code is NRN, Leeches, Medicinal, reviewed by the General and Plastic Surgery panel. The scoping review describes this as FDA approval for these uses, but the database entry records clearance. The indications wording sits in a scanned summary that could not be read here, so the listing alone does not state which uses are covered.

Names in clinical and traditional use

Hirudotherapy, medicinal leech therapy, leech therapy and leeching are used interchangeably in the sources reviewed. The French hospital study abbreviates hirudotherapy as HT and calls it an empirical medical technique, meaning it developed from observation and use rather than from a mechanism worked out in advance.

The term bloodletting covers several older methods of removing blood, of which leech application was one. In current surgical literature, leeches are described as one of several decongestion options, alongside stab incisions, heparin-soaked gauze and other drainage techniques, and the term is used for local drainage rather than general blood removal.

Device, drug and extract usage

In US device regulation the live animal is classified as a medical device named Leeches, Medicinal, rather than as a drug. Products derived from leech saliva, such as purified hirudin or topical saliva extract gels, are a separate subject, and evidence about live leeches should not be transferred to them or the reverse.

Surgical and hospital setting

In reconstructive surgery, leeches are applied by clinical staff to a flap, graft or replanted part when venous drainage is inadequate. The French hospital study describes a managed pathway covering ordering, storage, prescription, dispensing, application and disposal, with prescribed antibiotic prophylaxis, iron supplementation and blood monitoring, and notes risks of blood contamination for caregivers. It reports that clear guidelines were absent and that practices varied between hospitals.

Surgical teams combine leeches with other measures, and fingertip replantation reports describe patients on systemic anticoagulation while leeches are in use. This page does not describe application schedules or counts, which vary between reports and are decisions for the treating team.

Claimed mechanism

Surgeons and reviewers attribute the effect to substances in leech saliva, including hirudin, histamine-like products and hyaluronidase, which are described as keeping the bite site bleeding and aiding local circulation. The scoping review counts about 20 well-known bioactive compounds. These mechanistic descriptions explain why leeches are used and are not evidence that any particular outcome follows.

Elective and traditional settings

Outside hospitals, leeches are also applied for joint and other complaints. A German dermatology case report describes a patient who received two sessions from a non-medical practitioner for lower back pain and a heel spur, and later developed skin lesions at the application sites. Training and hygiene standards for such settings were not covered by the sources reviewed.

Established hospital use

A multicenter study describes medicinal leeches as indicated for salvage of tissue flaps, grafts or replants when venous congestion threatens tissue viability. Systematic reviews and case series of fingertip and artery-only digit replantation describe leeches as one way to drain a replanted part when a vein cannot be repaired.

Traditional and elective uses

A German review of complications lists the main indications of medical leech therapy as joint diseases such as osteoarthritis and epicondylitis, venous diseases and plastic surgery flaps. The scoping review says traditional systems applied leeches for inflammatory and congestive conditions, and Unani practice is reported to use them for chronic ulcers, eczema, varicose veins and musculoskeletal pain.

These traditional and elective claims differ in kind from surgical use. Reports of wider uses, including cancer-related effects of saliva extracts, come from laboratory research in the scoping review and are not clinical findings.

Venous congestion in replants and flaps

A retrospective Japanese study of 25 fingertip digits compared reactive leeching with prophylactic leeching. Complete survival was 8 of 12 digits (67 percent) with reactive use and 12 of 13 (92 percent) with prophylactic use, a difference that did not reach statistical significance, while early complications and reoperations were significantly more frequent in the reactive group. The authors list limitations: a small retrospective sample, several surgeons, and the possibility that some digits would have survived without leeches.

The same paper combined its data with the literature and found seven case series and no comparative studies, with 124 of 154 digits (81 percent) surviving. A systematic review of artery-only digit replantation covering 55 articles and 1,498 replantations found overall survival of 78.5 percent regardless of decongestion technique. The evidence base for flap and replant salvage is therefore mostly uncontrolled case series, and no randomized trials were identified in these sources.

A 2025 head and neck case series from one center reviewed seven patients: three recovered completely and four had partial tissue loss, and none lost the whole site. Its literature search found 16 articles, including three systematic reviews and 13 retrospective series of 6 to 277 cases.

Knee osteoarthritis as an elective use

A German randomized trial of 52 adults with knee osteoarthritis compared a single leech treatment with transcutaneous electrical nerve stimulation (TENS) in an unblinded crossover design. Because of phase effects, the confirmatory analysis was limited to the first period, in which pain and function scores improved with leeches over 21 days and not with TENS. No serious adverse effects were observed.

A 2014 systematic review of three randomized trials and one controlled trial with 237 patients reported moderate to strong evidence of reduced pain, stiffness and functional impairment, and no serious adverse events. A 2018 meta-analysis of four randomized trials with 264 patients found lower pain and WOMAC scores at one, four and seven weeks, rated overall evidence quality moderate, and also reported a significantly higher incidence of adverse events with leeches. Its authors advised cautious interpretation.

What the sources do not establish

The osteoarthritis trials are few, mostly unblinded and short, and none of the sources reviewed compared leeches with a sham procedure or reported guideline recommendations. Findings from surgical drainage and from knee osteoarthritis should not be carried to other conditions. Searches run for this page covered PubMed terms for leech therapy with knee osteoarthritis, Aeromonas, replantation, allergy and history, and did not locate a clinical guideline.

Infection with Aeromonas

Leeches carry gut bacteria of the genus Aeromonas, and surgical reports treat infection as the main concern. A multicenter retrospective study found surgical site infection in 7 of 59 patients (11.9 percent), all of whom had received antimicrobial prophylaxis, and Aeromonas isolates in four infections were resistant to the antibiotic chosen. A fingertip review cited reported infection rates of 2.4 to 36.2 percent.

Resistance is documented. A laboratory and clinical study traced rising ciprofloxacin-resistant Aeromonas infections after leech therapy to bacteria in the leeches, and a case report describes fatal sepsis after leech therapy for a flap in a patient with oral cancer, with matching Aeromonas strains in the patient and unused leeches. Authors of recent surgical reports describe antibiotic prophylaxis as essential during surgical use.

Bleeding and blood loss

Leech bites keep bleeding after the animal detaches, and anticoagulant medicine in surgical patients adds to this. In the fingertip study, hemoglobin fell by a median of 2.2 to 2.5 g/dL, one patient with preexisting anemia needed transfusion, and the literature review found transfusion in 12 of 43 patients (28 percent). The head and neck authors advise screening for coagulopathy and blood thinner use before surgical leech therapy.

Allergic and skin reactions

A German review lists infections, bleeding, anemia, allergic reactions and scarring as possible complications, and the scoping review names hypersensitivity, bleeding and infection as safety risks. The case report describes cutaneous pseudolymphoma, a benign reactive skin condition that can resemble lymphoma, appearing after leech therapy, with only nine earlier cases in the literature. It improved with topical steroid treatment. The authors suggest a delayed hypersensitivity reaction as one possible cause. The sources do not give how often allergy occurs.

Suitability and care boundaries

Sources describe distress in some patients and note that infection or tissue loss can follow surgical use. This page is educational and is not individual advice. Leech therapy for a threatened flap or replant is a surgical decision for the treating team, and fever, spreading redness, heavy or prolonged bleeding or breathing difficulty after a bite need urgent medical assessment. Elective use should not delay or replace necessary care for joint disease.